Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia

Abhishek Maiti; Courtney D. DiNardo; Naval G. Daver; Caitlin R. Rausch; Farhad Ravandi; Tapan M. Kadia; Naveen Pemmaraju; Gautam Borthakur; Prithviraj Bose; Ghayas C. Issa; Nicholas J. Short; Musa Yilmaz; Guillermo Montalban-Bravo; Alessandra Ferrajoli; Elias J. Jabbour; Nitin Jain; Maro Ohanian; Koichi Takahashi; Philip A Thompson; Sanam Loghavi; Kathryn S. Montalbano; Sherry Pierce; William G. Wierda; Hagop M. Kantarjian; Marina Konopleva

doi:10.1038/s41408-021-00410-w

Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia

Abhishek Maiti, Courtney D. DiNardo, Naval G. Daver, Caitlin R. Rausch, Farhad Ravandi, Tapan M. Kadia, Naveen Pemmaraju, Gautam Borthakur, Prithviraj Bose, Ghayas C. Issa, Nicholas J. Short, Musa Yilmaz, Guillermo Montalban-Bravo, Alessandra Ferrajoli, Elias J. Jabbour, Nitin Jain, Maro Ohanian, Koichi Takahashi, Philip A Thompson, Sanam LoghaviKathryn S. Montalbano, Sherry Pierce, William G. Wierda, Hagop M. Kantarjian, Marina Konopleva

Research output: Contribution to journal › Letter › peer-review

103 Scopus citations

Original language	English (US)
Article number	25
Journal	Blood cancer journal
Volume	11
Issue number	2
DOIs	https://doi.org/10.1038/s41408-021-00410-w
State	Published - Feb 2021

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1038/s41408-021-00410-w

Cite this

Maiti, A , DiNardo, CD , Daver, NG , Rausch, CR , Ravandi, F , Kadia, TM , Pemmaraju, N , Borthakur, G , Bose, P , Issa, GC , Short, NJ , Yilmaz, M , Montalban-Bravo, G , Ferrajoli, A , Jabbour, EJ , Jain, N , Ohanian, M , Takahashi, K, Thompson, PA, Loghavi, S, Montalbano, KS, Pierce, S, Wierda, WG , Kantarjian, HM & Konopleva, M 2021, 'Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia', Blood cancer journal, vol. 11, no. 2, 25. https://doi.org/10.1038/s41408-021-00410-w

@article{1dfd6b44aba0417a8a05b5580a7f95c7,

title = "Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia",

author = "Abhishek Maiti and DiNardo, {Courtney D.} and Daver, {Naval G.} and Rausch, {Caitlin R.} and Farhad Ravandi and Kadia, {Tapan M.} and Naveen Pemmaraju and Gautam Borthakur and Prithviraj Bose and Issa, {Ghayas C.} and Short, {Nicholas J.} and Musa Yilmaz and Guillermo Montalban-Bravo and Alessandra Ferrajoli and Jabbour, {Elias J.} and Nitin Jain and Maro Ohanian and Koichi Takahashi and Thompson, {Philip A} and Sanam Loghavi and Montalbano, {Kathryn S.} and Sherry Pierce and Wierda, {William G.} and Kantarjian, {Hagop M.} and Marina Konopleva",

note = "Funding Information: We would like t thank our patients, their familes and caregivers. A. Maiti. received support through the ASCO Young Investigator Award from the Conquer Cancer Foundation. This study was supported in part by the MD Anderson Cancer Center Support Grant CA016672 from the National Cancer Institute and the Research Project Grant Program (R01CA235622) from the National Institutes of Health. Funding Information: A.M. received research funding from Celgene Corporation. C.D.D. reports personal fees from Abbvie, Agios, Novartis, ImmuneOnc, Daiichi-Sankyo, Celgene, Jazz, and Notable Labs, outside the submitted work. N.G.D. reports grants from Abbvie, Genentech, Astellas, Daiichi-Sankyo, Pfizer, BMS, Immunogen, Novimmune, Forty Seven, Inc., personal fees from Abbvie, Genentech, Astellas, Daiichi-Sankyo, Pfizer, BMS, Immunogen, Jazz Pharmaceuticals, Trillium, Forty Seven, Inc., Gilead, Kite, and Novartis. C.R.R.: none. F.R. received personal fees and research grants from Abbvie. N.P. reports personal fees from Pacylex Pharmaceuticals, Incyte, LFB Biotechnologies, Roche Diagnostics, and Blueprint Medicines, grants and other from Affymetrix, grants from SagerStrong Foundation, personal fees and other from Novartis, personal fees, nonfinancial support, and other from Stemline Therapeutics and AbbVie, personal fees and nonfinancial support from Celgene, MustangBio, and DAVA Oncology, and other from Samus Therapeutics, Cellectis, Daiichi- Funding Information: Sankyo, and Plexxikon, outside the submitted work. G.B.: research funding— AbbVie, Incyte, Janssen, GSK, and Cyclacel; consultancy and research funding —BioLine Rx; consultancy—NKarta and PTC Therapeutics; research funding— Oncoceutics, Inc. M.O. and G.M.B: none. N.J.S. reports grants from Takeda Oncology and Astellas; personal fees from Takeda Oncology, AstraZeneca, and Amgen. Y.A. and T.M.K.: none. K.T. has received personal fees for service on the advisory boards of Symbio Pharmaceuticals, GSK, and Celgene. M.Y.: none. N.J.: consultancy, honoraria, membership on an entity{\textquoteright}s Board of Directors or advisory committees, and research funding—AbbVie, Pharmacyclics, an AbbVie company, Janssen Pharmaceuticals, Inc., Genentech, Pfizer, ADC Therapeutics, AstraZeneca, Servier, Verastem, Precision Biosciences, and Adaptive Biotechnologies; research funding—BMS, Incyte, and Cellectis. P.B. reports research grant and personal fees from Incyte, Celgene, CTI Biopharma, Kartos Therapeutics, and BluePrint Medicines, and research grants from Constellation Pharmaceuticals, NS Pharma, Promedior, Pfizer, and Astellas. A.F.: none. G.C.I. received research funding from Celgene and served on an advisory board for Novartis. E.J.J.: consultancy research funding from Takeda, BMS, Adaptive, Amgen, AbbVie, Pfizer, and Cyclacel LTD; research grants with Amgen, Abbvie, Spectrum, BMS, Takeda, Pfizer, and Adaptive. P.A.T. reports research funding to the institution and consultancy/honorarium paid to the institution from Pharmacyclics, Abbvie, and Amgen; consultancy/honorarium paid to the institution from Genentech, Gilead Scienes, and Janssen-Cilag; research funding to the institution from Pfizer. K.S.M., S.A.P., and W.G.W.: none. H.M.K.: grants and other from AbbVie, Agios, Amgen, Immunogen, and Pfizer; grants from Ariad, Astex, BMS, Cyclacel, Daiichi-Sankyo, Jazz Pharma, Novartis, Actinium, and Takeda, outside the submitted work. M.Y.K. has received grants from NIH, NCI, Abbvie, Genentech, Stemline Therapeutics, Forty Seven, Inc., Eli Lilly, Cellectis, Calithera, Ablynx, and AstraZeneca; consulting/honorarium from AbbVie, Genentech, F. Hoffman La-Roche, Stemline Therapeutics, Amgen, Forty Seven, Inc., and Kisoji; clinical trial support from Ascentage; stocks/royalties in Reata Pharmaceutical.",

year = "2021",

month = feb,

doi = "10.1038/s41408-021-00410-w",

language = "English (US)",

volume = "11",

journal = "Blood cancer journal",

issn = "2044-5385",

publisher = "Springer Nature",

number = "2",

}

TY - JOUR

T1 - Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia

AU - Maiti, Abhishek

AU - DiNardo, Courtney D.

AU - Daver, Naval G.

AU - Rausch, Caitlin R.

AU - Ravandi, Farhad

AU - Kadia, Tapan M.

AU - Pemmaraju, Naveen

AU - Borthakur, Gautam

AU - Bose, Prithviraj

AU - Issa, Ghayas C.

AU - Short, Nicholas J.

AU - Yilmaz, Musa

AU - Montalban-Bravo, Guillermo

AU - Ferrajoli, Alessandra

AU - Jabbour, Elias J.

AU - Jain, Nitin

AU - Ohanian, Maro

AU - Takahashi, Koichi

AU - Thompson, Philip A

AU - Loghavi, Sanam

AU - Montalbano, Kathryn S.

AU - Pierce, Sherry

AU - Wierda, William G.

AU - Kantarjian, Hagop M.

AU - Konopleva, Marina

N1 - Funding Information: We would like t thank our patients, their familes and caregivers. A. Maiti. received support through the ASCO Young Investigator Award from the Conquer Cancer Foundation. This study was supported in part by the MD Anderson Cancer Center Support Grant CA016672 from the National Cancer Institute and the Research Project Grant Program (R01CA235622) from the National Institutes of Health. Funding Information: A.M. received research funding from Celgene Corporation. C.D.D. reports personal fees from Abbvie, Agios, Novartis, ImmuneOnc, Daiichi-Sankyo, Celgene, Jazz, and Notable Labs, outside the submitted work. N.G.D. reports grants from Abbvie, Genentech, Astellas, Daiichi-Sankyo, Pfizer, BMS, Immunogen, Novimmune, Forty Seven, Inc., personal fees from Abbvie, Genentech, Astellas, Daiichi-Sankyo, Pfizer, BMS, Immunogen, Jazz Pharmaceuticals, Trillium, Forty Seven, Inc., Gilead, Kite, and Novartis. C.R.R.: none. F.R. received personal fees and research grants from Abbvie. N.P. reports personal fees from Pacylex Pharmaceuticals, Incyte, LFB Biotechnologies, Roche Diagnostics, and Blueprint Medicines, grants and other from Affymetrix, grants from SagerStrong Foundation, personal fees and other from Novartis, personal fees, nonfinancial support, and other from Stemline Therapeutics and AbbVie, personal fees and nonfinancial support from Celgene, MustangBio, and DAVA Oncology, and other from Samus Therapeutics, Cellectis, Daiichi- Funding Information: Sankyo, and Plexxikon, outside the submitted work. G.B.: research funding— AbbVie, Incyte, Janssen, GSK, and Cyclacel; consultancy and research funding —BioLine Rx; consultancy—NKarta and PTC Therapeutics; research funding— Oncoceutics, Inc. M.O. and G.M.B: none. N.J.S. reports grants from Takeda Oncology and Astellas; personal fees from Takeda Oncology, AstraZeneca, and Amgen. Y.A. and T.M.K.: none. K.T. has received personal fees for service on the advisory boards of Symbio Pharmaceuticals, GSK, and Celgene. M.Y.: none. N.J.: consultancy, honoraria, membership on an entity’s Board of Directors or advisory committees, and research funding—AbbVie, Pharmacyclics, an AbbVie company, Janssen Pharmaceuticals, Inc., Genentech, Pfizer, ADC Therapeutics, AstraZeneca, Servier, Verastem, Precision Biosciences, and Adaptive Biotechnologies; research funding—BMS, Incyte, and Cellectis. P.B. reports research grant and personal fees from Incyte, Celgene, CTI Biopharma, Kartos Therapeutics, and BluePrint Medicines, and research grants from Constellation Pharmaceuticals, NS Pharma, Promedior, Pfizer, and Astellas. A.F.: none. G.C.I. received research funding from Celgene and served on an advisory board for Novartis. E.J.J.: consultancy research funding from Takeda, BMS, Adaptive, Amgen, AbbVie, Pfizer, and Cyclacel LTD; research grants with Amgen, Abbvie, Spectrum, BMS, Takeda, Pfizer, and Adaptive. P.A.T. reports research funding to the institution and consultancy/honorarium paid to the institution from Pharmacyclics, Abbvie, and Amgen; consultancy/honorarium paid to the institution from Genentech, Gilead Scienes, and Janssen-Cilag; research funding to the institution from Pfizer. K.S.M., S.A.P., and W.G.W.: none. H.M.K.: grants and other from AbbVie, Agios, Amgen, Immunogen, and Pfizer; grants from Ariad, Astex, BMS, Cyclacel, Daiichi-Sankyo, Jazz Pharma, Novartis, Actinium, and Takeda, outside the submitted work. M.Y.K. has received grants from NIH, NCI, Abbvie, Genentech, Stemline Therapeutics, Forty Seven, Inc., Eli Lilly, Cellectis, Calithera, Ablynx, and AstraZeneca; consulting/honorarium from AbbVie, Genentech, F. Hoffman La-Roche, Stemline Therapeutics, Amgen, Forty Seven, Inc., and Kisoji; clinical trial support from Ascentage; stocks/royalties in Reata Pharmaceutical.

PY - 2021/2

Y1 - 2021/2

UR - http://www.scopus.com/inward/record.url?scp=85101031758&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85101031758&partnerID=8YFLogxK

U2 - 10.1038/s41408-021-00410-w

DO - 10.1038/s41408-021-00410-w

M3 - Letter

C2 - 33563904

AN - SCOPUS:85101031758

SN - 2044-5385

VL - 11

JO - Blood cancer journal

JF - Blood cancer journal

IS - 2

M1 - 25

ER -

Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this